

JUBILANT LIFE SCIENCE (BVI) LIMITED

Balance Sheet

As at 31st Mar	Notes No	2015	2015	2014	2014
		USD	INR (' In Thousands)	USD	INR (' In Thousands)
I. EQUITY AND LIABILITIES					
Shareholders' Funds					
Share capital	1	3,972,501	198,793	3,972,501	198,793
Reserves & surplus	2	(31,375)	47,527	(25,505)	37,671
		3,941,126	246,320	3,946,996	236,465
Current liabilities					
Trade payables	3	4,430	277	1,661	99
		4,430	277	1,661	99
Total		3,945,555	246,597	3,948,657	236,564
II. ASSETS					
Non-current investments	4	3,944,502	246,531	3,944,502	236,315
		3,944,502	246,531	3,944,502	236,315
Current assets					
Cash & bank balances	5	732	46	3,926	235
Short-term loans and advances	6	322	20	229	14
		1,053	66	4,155	249
Total		3,945,555	246,597	3,948,657	236,564

Prakash C Bisht
CFO (Ingredients) & Sr. VP (Group Accounts)
Place : Noida
Date : 29th April, 2015

JUBILANT LIFE SCIENCE (BVI) LIMITED
Statement of Profit and Loss

For the year ended 31st March,		Notes No	2015	2015	2014	2014
			USD	INR (' In Thousands)	USD	INR (' In Thousands)
EXPENSES						
Other expenses	7		5,870	362	5,902	358
Total expenses			5,870	362	5,902	358
Profit for the Year			(5,870)	(362)	(5,902)	(358)

Prakash C Bisht
CFO (Ingredients) & Sr. VP (Group Accounts)
Place : Noida
Date : 29th April, 2015

JUBILAANT LIFE SCIENCES (BVI) LIMITED

CASH FLOW STATEMENT

Cash flow Statement for the Year Ended	2015	2015	2014	2014
	USD	INR (' In Thousands)	USD	INR (' In Thousands)
A. Cash flows from operating activities				
Net income before minority interest	(5,870)	(362)	(5,902)	(358)
Operating profit before working capital changes	(5,870)	(362)	(5,902)	(358)
Adjustments for :				
(Increase)/Decrease in trade and other receivables	(93)	(6)	(3)	(0)
Increase/(Decrease) in trade and other payables	2,769	169	672	41
Net cash inflow/(outflow) in course of operating activities	(3,194)	(198)	(5,233)	(318)
B. Cash flow arising from investing activities :				
(Purchase)/sale of investments (net)(Including in Subsidiaries)	-	-	(40,000)	(2,416)
Net cash inflow/(outflow) in course of investing activities	-	-	(40,000)	(2,416)
C. Cash flow arising from financing activities :				
Proceeds from issue of share capital(including share premium & net of share issue expenses)	-	-	45,000	2,718
Net cash inflow/(outflow) in course of financing activities	-	-	45,000	2,718
D. Foreign currency translation difference arising on consolidation				
		8		25
Net Increase in cash & cash equivalents (A+B+C)	(3,194)	(189)	(233)	9
Add: cash & cash equivalents at the beginning of year(including balance in dividend accounts)	3,926	235	4,159	226
Cash & cash equivalents at the close of the year(including balance in dividend accounts)	732	46	3,926	235

Notes:

1) Cash Flow Statement has been prepared under the indirect method as set out in Accounting Standard 3 (AS-3)- "Cash Flow Statements"

Prakash C Bisht

CFO (Ingredients) & Sr. VP (Group Accounts)

Place : Noida

Date : 29th April, 2015

JUBILANT LIFE SCIENCE (BVI) LIMITED
Notes to the Financial Statements

As at 31st Mar	2015	2015	2014	2014
Particulars	USD	INR (' In Thousands)	USD	INR (' In Thousands)
1. SHARE CAPITAL				
Authorized				
10,000,000 equity shares of USD 1 each (Previous Year 10,000,000 equity shares of USD 1 each)	-	-	-	-
	-	-	-	-
Issued & Subscribed				
3,972,501 equity shares of USD 1 each (Previous Year 3,972,501 equity shares of USD 1 each)	3,972,501	198,793	3,972,501	198,793
	3,972,501	198,793	3,972,501	198,793
Paid up				
3,972,501 equity shares of USD 1 each (Previous Year 3,972,501 equity shares of USD 1 each)	3,972,501	198,793	3,972,501	198,793
	3,972,501	198,793	3,972,501	198,793

1.1) The Company has only one class of shares referred to as equity shares having par value of USD 1 each. Each holder of equity shares is entitled to one vote per share.

1.2) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amounts. However, no such preferential amounts exist currently. The distribution will be in proportion to the number of equity shares held by the shareholders.

3) The details of shareholders holding more than 5% shares in the company

As at 31st March	2015	2015	2014	2014
Name of the shareholder	USD	INR (' In Thousands)	USD	INR (' In Thousands)
Jubilant Life Sciences (BVI) Ltd, British Virgin Islands-the Holding Company	3,972,501	100.00%	3,972,501	100.00%

4) The reconciliation of the number of shares outstanding as at beginning and at the end of reporting period

As at 31st March	2015	2015	2014	2014
Name of the shareholder	No.	'INR (' In Thousands)	No.	'INR (' In Thousands)
Numbers of shares at the beginning	3,972,501	198,793	3,927,501.00	196,372
Add: Shares issued during the year	-	-	45,000.00	2,421
Numbers of shares at the end	3,972,501	198,793	3,972,501	198,793

5) Shares held by holding company/ultimate holding company and/or their subsidiaries/associates

Out of the equity Shares issued by the company, shares held by it's holding company/ultimate holding company and/or their subsidiaries/associates are as below:

As at 31st March	2015	2015	2014	2014
Particulars	No.	'INR (' In Thousands)	No.	'INR (' In Thousands)
Drug Discovery and Development Solutions Ltd-Singapore Holding Company 3,972,501 equity shares of USD 1 each	3,972,501	198,793	3,972,501	198,793

JUBILANT LIFE SCIENCE (BVI) LIMITED
Notes to the Financial Statements

As at 31st Mar	2015	2015	2014	2014
Particulars	USD	INR (' In Thousands)	USD	INR (' In Thousands)
2. RESERVES AND SURPLUS				
Foreign Currency Translation Reserve				
Foreign Currency Translation Reserve Opening	-	38,981.06	-	-
Foreign Currency Translation Reserve During the Year	-	10,217.33	-	38,981.06
	-	49,198.38	-	38,981.06
Surplus as per P&L Account				
As per last Balance Sheet	(25,505)	(1,310)	(19,603)	(952)
Add: Net Profit after tax transferred from Statement of Profit and Loss	(5,870)	(362)	(5,902)	(358)
	(31,375)	(1,671)	(25,505)	(1,310)
	(31,375)	47,527	(25,505)	37,671
3. TRADE PAYABLES				
Trade payables-others	4,430	277	1,661	99
	4,430	277	1,661	99
4. NON CURRENT INVESTMENTS				
Investment in Subsidiary/Fellow Subsidiaries Companies				
Jubilant Biosys (BVI) LTD	1,397,501	87,344	1,397,501	83,274
1371501 shares of USD 1 each				
Jubilant Drug Development Pte Ltd	2,547,001	159,188	2,547,001	152,591
1371501 shares of USD 1 each				
	3,944,502	246,531	3,944,502	236,315
5. CASH AND BANK BALANCES				
Balances with banks:				
- On current accounts	732	46	3,926	235
	732	46	3,926	235
6. SHORT TERM LOANS AND ADVANCES				
- Prepaid Expenses	322	20	229	14
	322	20	229	14
7. OTHER EXPENSE				
Legal , professional & consultancy charges	5,830	359	5,762	350
Bank Charges	40	2	140	8
	5,870	362	5,902	358